ChemoCentryx, Inc.
CCXI · NASDAQ
6/30/2022 | 3/31/2022 | 12/31/2021 | 9/30/2021 | |
|---|---|---|---|---|
| Market Cap | $1,765,179 | $1,775,833 | $2,552,742 | $1,195,187 |
| - Cash | $44,396 | $40,577 | $49,978 | $93,726 |
| + Debt | $72,003 | $72,659 | $23,635 | $72,952 |
| Enterprise Value | $1,792,786 | $1,807,915 | $2,526,399 | $1,174,413 |
| Revenue | $11,763 | $5,459 | $2,611 | $17,691 |
| % Growth | 115.5% | 109.1% | -85.2% | – |
| Gross Profit | $10,960 | $5,254 | $2,309 | $17,691 |
| % Margin | 93.2% | 96.2% | 88.4% | 100% |
| EBITDA | -$30,041 | -$36,994 | -$44,259 | -$20,636 |
| % Margin | -255.4% | -677.7% | -1,695.1% | -116.6% |
| Net Income | -$32,237 | -$39,205 | -$35,781 | -$22,307 |
| % Margin | -274.1% | -718.2% | -1,370.4% | -126.1% |
| EPS Diluted | -0.45 | -0.55 | -0.51 | -0.32 |
| % Growth | 18.2% | -7.8% | -59.4% | – |
| Operating Cash Flow | -$26,126 | $8,831 | -$10,887 | -$25,316 |
| Capital Expenditures | -$404 | -$224 | -$493 | -$4,350 |
| Free Cash Flow | -$26,530 | $8,607 | -$11,380 | -$29,666 |